Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer-Reference-Cited by-同舟云学术

Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer

Published:2020-01 Issue:10 Volume:9 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin. Transl. Immunol.

Author:

Liu Heping¹,Ma Yuxiang²,Yang Chaopin³⁴,Xia Shangzhou¹,Pan Qiuzhong³⁴,Zhao Hongyun²,Fang Wenfeng⁵,Chen Xi⁵,Zhang Yang²,Zou Benyan⁵,Li Qiuyuan⁵,Wan Yang¹,Chen Hao³⁴,Tang Yan³⁴,Zhao Jingjing³⁴,Weng Desheng³⁴,Xia Liming¹,Zhang Li⁵,Xia Jianchuan³¹⁴^ORCID

Affiliation:

1. Guangzhou Yiyang Biotechnology Company Ltd Guangzhou China

2. Department of Clinical Research Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China

3. Department of Biotherapy Sun Yat‐sen University Cancer Center Guangzhou China

4. Collaborative Innovation Center for Cancer Medicine State Key Laboratory of Oncology in South China Sun Yat‐sen University Cancer Center Guangzhou China

5. Department of Medical Oncology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1154

Reference27 articles.

1. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

2. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

3. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors